Poly-γ-Glutamic Acid Complexed With Alum Induces Cross-Protective Immunity of Pandemic H1N1 Vaccine

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2019 Jul 30

PMID 31354739

Citations 15

Authors

Quyen Thi Nguyen

Chaewon Kwak

Wang Sik Lee

Jaemoo Kim

Jinyoung Jeong

Moon Hee Sung

Jihyun Yang

Haryoung Poo

Affiliations

Soon will be listed here.

Abstract

The use of a good vaccine adjuvant may induce a higher immunogenicity profile of vaccine antigens. Here, we developed a new adjuvant by combining poly-γ-glutamic acid (γ-PGA) with alum (PGA/Alum) and investigated its ability to enhance the immunogenicity and the cross-reactive efficacy of pandemic H1N1 (pH1N1) influenza vaccine antigen. PGA/Alum enhanced antigen delivery to draining lymph nodes and antigen-specific immunogenicity in mice using OVA as a model antigen. It also greatly increased OVA-specific antibody production, cytotoxic T lymphocyte (CTL) activity, and antibody-dependent cellular cytotoxicity (ADCC). These abilities of PGA/Alum improved the protective efficacy of pH1N1 vaccine antigen by increasing hemagglutination-inhibition titers, enhancing ADCC and CTL activity, and speeding viral clearance following homologous viral challenge. Importantly, the cross-protective efficacy of pH1N1 vaccine against heterologous viruses [A/Puerto Rico/8/34 (H1N1) and A/Hong Kong/1/1968 (H3N2)] was significantly enhanced by PGA/Alum, and cross-reactive ADCC and CTL activities were observed. Together, our results strongly suggest that PGA/Alum may be a promising vaccine adjuvant for preventing influenza and other infectious diseases.

Citing Articles

Identification of tumor antigens for mRNA vaccines and ferroptosis-related landscape in esophageal squamous cell carcinoma.

Zeng Q, Chen B, Wang W Transl Cancer Res. 2024; 13(6):2860-2876.

PMID: 38988947 PMC: 11231762. DOI: 10.21037/tcr-23-2027.

Charge neutralized poly(β-amino ester) polyplex nanoparticles for delivery of self-amplifying RNA.

Dastgerdi N, Gumus N, Bayraktutan H, Jackson D, Polra K, McKay P Nanoscale Adv. 2024; 6(5):1409-1422.

PMID: 38419881 PMC: 10898429. DOI: 10.1039/d3na00794d.

Poly (γ) glutamic acid: a unique microbial biopolymer with diverse commercial applicability.

Elbanna K, Alsulami F, Neyaz L, Abulreesh H Front Microbiol. 2024; 15:1348411.

PMID: 38414762 PMC: 10897055. DOI: 10.3389/fmicb.2024.1348411.

Modulation of immune response by nanoparticle-based immunotherapy against food allergens.

Krishna S, Farhana S, T P A, Hussain S, Viswanad V, Nasr M Front Immunol. 2023; 14:1229667.

PMID: 37744376 PMC: 10515284. DOI: 10.3389/fimmu.2023.1229667.

Heterologous immunity induced by 1 generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine.

Patel R, Agrawal B Front Immunol. 2022; 13:952229.

PMID: 36045689 PMC: 9420909. DOI: 10.3389/fimmu.2022.952229.

References

Sozzani S, Allavena P, Vecchi A, Mantovani A . The role of chemokines in the regulation of dendritic cell trafficking. J Leukoc Biol. 1999; 66(1):1-9. DOI: 10.1002/jlb.66.1.1. View

Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E . CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999; 99(1):23-33. DOI: 10.1016/s0092-8674(00)80059-8. View

Sallusto F, Lanzavecchia A . Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev. 2001; 177:134-40. DOI: 10.1034/j.1600-065x.2000.17717.x. View

Boon A, de Mutsert G, van Baarle D, Smith D, Lapedes A, Fouchier R . Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J Immunol. 2004; 172(4):2453-60. DOI: 10.4049/jimmunol.172.4.2453. View

Deng Y, Jing Y, Campbell A, Gravenstein S . Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol. 2004; 172(6):3437-46. DOI: 10.4049/jimmunol.172.6.3437. View

Ellenberg S, Foulkes M, Midthun K, Goldenthal K . Evaluating the safety of new vaccines: summary of a workshop. Am J Public Health. 2005; 95(5):800-7. PMC: 1449258. DOI: 10.2105/AJPH.2004.039438. View

Sung M, Park C, Kim C, Poo H, Soda K, Ashiuchi M . Natural and edible biopolymer poly-gamma-glutamic acid: synthesis, production, and applications. Chem Rec. 2005; 5(6):352-66. DOI: 10.1002/tcr.20061. View

Guy B . The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol. 2007; 5(7):505-17. DOI: 10.1038/nrmicro1681. View

Kim T, Lee T, Bae H, Hahm J, Kim Y, Park C . Oral administration of high molecular mass poly-gamma-glutamate induces NK cell-mediated antitumor immunity. J Immunol. 2007; 179(2):775-80. DOI: 10.4049/jimmunol.179.2.775. View

10.

Quan F, Compans R, Nguyen H, Kang S . Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol. 2007; 82(3):1350-9. PMC: 2224423. DOI: 10.1128/JVI.01615-07. View

11.

Alvarez D, Vollmann E, von Andrian U . Mechanisms and consequences of dendritic cell migration. Immunity. 2008; 29(3):325-42. PMC: 2818978. DOI: 10.1016/j.immuni.2008.08.006. View

12.

Lee T, Kim Y, Yoon S, Choi J, Yang J, Kim C . Oral administration of poly-gamma-glutamate induces TLR4- and dendritic cell-dependent antitumor effect. Cancer Immunol Immunother. 2009; 58(11):1781-94. PMC: 7370862. DOI: 10.1007/s00262-009-0689-4. View

13.

Didierlaurent A, Morel S, Lockman L, Giannini S, Bisteau M, Carlsen H . AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol. 2009; 183(10):6186-97. DOI: 10.4049/jimmunol.0901474. View

14.

Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, Pellegrini M . Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine. 2010; 28(45):7331-6. DOI: 10.1016/j.vaccine.2010.08.075. View

15.

Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V . Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011; 29(13):2461-73. DOI: 10.1016/j.vaccine.2011.01.011. View

16.

Chung A, Navis M, Isitman G, Centre R, Finlayson R, Bloch M . Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol. 2011; 24(2):171-5. PMC: 3070001. DOI: 10.1089/vim.2010.0108. View

17.

Uto T, Akagi T, Yoshinaga K, Toyama M, Akashi M, Baba M . The induction of innate and adaptive immunity by biodegradable poly(γ-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway. Biomaterials. 2011; 32(22):5206-12. DOI: 10.1016/j.biomaterials.2011.03.052. View

18.

Lim Y, Shim S, Noh Y, Lee K, Choi D, Uyama H . Bioderived polyelectrolyte nanogels for robust antigen loading and vaccine adjuvant effects. Small. 2011; 7(23):3281-6. DOI: 10.1002/smll.201101836. View

19.

Levitz S, Golenbock D . Beyond empiricism: informing vaccine development through innate immunity research. Cell. 2012; 148(6):1284-92. PMC: 3308125. DOI: 10.1016/j.cell.2012.02.012. View

20.

Smalls-Mantey A, Doria-Rose N, Klein R, Patamawenu A, Migueles S, Ko S . Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol. 2012; 86(16):8672-80. PMC: 3421757. DOI: 10.1128/JVI.00287-12. View